Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Shin Nippon Biomedical Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Shin Nippon Biomedical Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 14.7% bzw. 11.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.9% betragen.

Wichtige Informationen

14.7%

Wachstumsrate der Gewinne

14.7%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	24.3%
Wachstumsrate der Einnahmen	11.4%
Zukünftige Eigenkapitalrendite	17.9%
Analystenabdeckung	Low
Zuletzt aktualisiert	10 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10

Recent updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 21

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Mar 12

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Feb 27

Gewinn- und Umsatzwachstumsprognosen

TSE:2395 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	37,500	7,700	3,577	8,577	1
3/31/2026	34,000	6,700	-189	7,811	1
3/31/2025	30,500	4,300	-5,117	5,383	1
3/31/2024	26,450	5,531	-6,499	2,107	N/A
12/31/2023	26,703	5,503	N/A	N/A	N/A
9/30/2023	26,626	4,607	-4,074	1,899	N/A
6/30/2023	26,848	5,489	N/A	N/A	N/A
3/31/2023	25,090	6,060	-950	4,004	N/A
12/31/2022	21,173	6,231	N/A	N/A	N/A
9/30/2022	20,135	8,043	4,382	7,170	N/A
6/30/2022	18,753	7,245	N/A	N/A	N/A
3/31/2022	17,748	7,127	4,339	5,952	N/A
12/31/2021	17,636	7,432	N/A	N/A	N/A
9/30/2021	16,068	6,025	4,075	5,301	N/A
6/30/2021	14,978	4,844	N/A	N/A	N/A
3/31/2021	15,110	3,661	3,629	4,746	N/A
12/31/2020	14,910	2,421	N/A	N/A	N/A
9/30/2020	15,175	2,812	1,389	2,706	N/A
6/30/2020	15,004	3,234	N/A	N/A	N/A
3/31/2020	14,561	2,550	1,788	3,018	N/A
12/31/2019	13,497	1,990	N/A	N/A	N/A
9/30/2019	13,167	1,915	1,784	2,988	N/A
6/30/2019	14,676	1,524	N/A	N/A	N/A
3/31/2019	15,658	1,950	1,794	2,892	N/A
12/31/2018	17,337	-49	N/A	N/A	N/A
9/30/2018	17,928	-993	1,631	2,943	N/A
6/30/2018	16,937	-2,566	N/A	N/A	N/A
3/31/2018	16,600	-3,555	326	1,344	N/A
12/31/2017	17,186	-1,072	N/A	N/A	N/A
9/30/2017	17,714	327	N/A	280	N/A
6/30/2017	17,230	260	N/A	N/A	N/A
3/31/2017	17,244	-915	N/A	-849	N/A
12/31/2016	15,880	-1,821	N/A	N/A	N/A
9/30/2016	15,269	-1,273	N/A	-3,109	N/A
6/30/2016	14,922	-1,475	N/A	N/A	N/A
3/31/2016	14,750	2,646	N/A	-3,339	N/A
12/31/2015	15,637	2,060	N/A	N/A	N/A
9/30/2015	16,344	401	N/A	-2,379	N/A
6/30/2015	17,164	1,546	N/A	N/A	N/A
3/31/2015	17,835	-1,385	N/A	-2,156	N/A
12/31/2014	18,058	-417	N/A	N/A	N/A
9/30/2014	17,161	-599	N/A	-1,377	N/A
6/30/2014	17,132	-1,074	N/A	N/A	N/A
3/31/2014	16,926	-754	N/A	-1,620	N/A
12/31/2013	16,993	-1,443	N/A	N/A	N/A
9/30/2013	17,513	-1,185	N/A	-1,495	N/A
6/30/2013	16,837	-1,044	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 2395Das prognostizierte Gewinnwachstum (14.7% pro Jahr) liegt über der Sparquote (0.2%).

Ertrag vs. Markt: 2395Die Erträge des Unternehmens (14.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (8.4% pro Jahr).

Hohe Wachstumserträge: 2395Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 2395Die Einnahmen des Unternehmens (11.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (3.9% pro Jahr).

Hohe Wachstumseinnahmen: 2395Die Einnahmen des Unternehmens (11.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 2395Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.9 %).

Shin Nippon Biomedical Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 19%

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Price target decreased by 13% to JP¥3,150

Consensus revenue estimates fall by 14%

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Price target increased by 15% to JP¥4,150

Recent updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus EPS estimates fall by 19%

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to JP¥3,150

Upcoming dividend of JP¥30.00 per share

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024

Investor sentiment deteriorates as stock falls 17%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024

New minor risk - Share price stability

Upcoming dividend of JP¥20.00 per share at 2.6% yield

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.

Price target increased by 15% to JP¥4,150

Consensus EPS estimates fall by 20%, revenue upgraded

Full year 2023 earnings: EPS exceeds analyst expectations

Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2023

Investor sentiment deteriorates as stock falls 21%

Upcoming dividend of JP¥30.00 per share at 1.5% yield

Now 20% undervalued

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 20%, revenue upgraded

Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023

Third quarter 2023 earnings released: JP¥1.63 loss per share (vs JP¥41.89 profit in 3Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

No independent directors

Second quarter 2023 earnings released: EPS: JP¥59.45 (vs JP¥40.28 in 2Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023

Price target increased to JP¥3,600

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: JP¥46.70 (vs JP¥43.86 in 1Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Revises Earnings Guidance for the Six Months Ending September 30, 2022 and Fiscal Year Ending March 31, 2022

Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) made a tender offer to acquire Ina Research Inc. (TSE:2176) from its shareholder for ¥2.7 billion.

Investor sentiment improved over the past week

Full year 2022 earnings: EPS exceeds analyst expectations

Shin Nippon Biomedical Laboratories, Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 28, 2022

No independent directors

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2022 Results on May 06, 2022

Investor sentiment improved over the past week

Upcoming dividend of JP¥40.00 per share

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shin Nippon Biomedical Laboratories, Ltd. Provides Special Dividend Guidance the Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥40.28 (vs JP¥11.91 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS JP¥43.86 (vs JP¥15.45 in 1Q 2021)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2021 and Year Ending March 31, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS JP¥87.94 (vs JP¥61.25 in FY 2020)

Upcoming dividend of JP¥5.00 per share

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2021 Results on May 10, 2021